Update on hepatitis C: treatment and care and future directions
|
|
|
- Shanon Hunter
- 10 years ago
- Views:
Transcription
1 Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; St Vincent s Hospital, Darlinghurst
2 Hepatitis C update Liver disease progression Staging of liver disease Current therapeutic issues Future directions in therapy
3 Hepatitis C natural history Determinants of liver disease progression Prior evidence ALT level Alcohol intake Age at infection Co-infection (HIV or HBV) Gender Stage of fibrosis New evidence Obesity/hepatic steatosis Smoking Cannabis No/limited evidence HCV genotype HCV viral load
4 Hepatitis C liver disease staging Methods Clinical examination Serum transaminases (ALT, AST) Poor correlation with fibrosis Normal in 25% (of whom 30-35% progress to significant fibrosis) Surrogate markers Albumin, prothrombin time, bilirubin Liver biopsy (current gold standard)
5 Hepatitis C liver disease staging Viral - HBV and HCV Cause Immune - Autoimmune, PBC, PSC Toxic - Alcohol Metabolic - Nonalcoholic fatty liver disease (NAFLD) Genetic - Haemochromatosis Stage - fibrosis F1 F2 F3 F4 cirrhosis
6 Hepatitis C liver disease staging
7 Hepatitis C liver disease staging Alternative methods Biochemical surrogate markers APRI (AST/platelet ratio) FIB-4 (age, AST, platelet, bilirubin) Fibrotest Hepascore Transient Elastography (Fibroscan)
8 Hepatitis C liver disease staging: fibroscan
9 Hepatitis C liver disease staging: fibroscan 2.5 cm Explored volume 1 cm 4 cm
10 Hepatitis C liver disease staging: fibroscan Range 2.5 kpa 75 kpa Depth (mm) Depth (mm) Depth (mm) Time (ms) Time (ms) Time (ms) V S = 1.1 m/s V S = 1.6 m/s V S = 3.0 m/s E ~ 3 kpa E ~ 8 kpa E ~ 27 kpa F0 F1 F2 F3 F4 Multiple measurements : success rate should be at least 60% IQR should not be >30% of median value
11 Hepatitis C liver disease staging: fibroscan
12 Hepatitis C liver disease staging: fibroscan 711 subjects 95 with cirrhosis kpa No varices (2/3) No Child-Pugh B or C No past history ascites No hepatocellular carcinoma No past history variceal bleeding >90% NPV for above complications Foucher et al 2006
13 Hepatitis C treatment Sustained Virological Response? PEG-IFN+RBV weeks IFN-α2b+RBV 48 weeks 61%-65% PEG-IFN 48 weeks 41% IFN-α2b 48 weeks 25%-29% IFN-α2b 24 weeks 15%-22% 8%-12% 15 years
14 Hepatitis C treatment HCV treatment through HSD: Removal of mandatory liver biopsy NCHECR 2009
15 Hepatitis C treatment Issues Positive Curative potential (50 80%) Improving response rates and clinical experience Government-subsidized Some expansion of access removal of liver biopsy Negative Toxicity: flu-like symptoms, depression, anaemia, lethargy Requirement for contraception during and 6 months following Tertiary hospital focused
16 Hepatitis C treatment HCV treatment response definitions NR Relapse Viral load RVR EVR ETR SVR post-rx Treatment weeks
17 Hepatitis C treatment SVR in RVR HCV genotype 1: PEG-IFN2a/RBV % RVR non-rvr 800 mg x 24 wks 1000/1200 mg x 24 wks 800 mg x 48 wks 1000 / 1200 mg x 48 wks Jensen et al Hepatology 2006 RVR = < 50 IU/ml at week 4; 20%
18 Hepatitis C treatment Time to respond and SVR: genotype Null 20% Week 4 15% Partial 15% Week 12 35% Week 24 15% Ferrenci et al. J Hepatology 2005 SVR (%) Week HCV RNA (-)
19 Hepatitis C treatment Factors associated with poorer SVR HCV genotype 1 HCV viral load (genotype 1) Severe fibrosis cirrhosis High body weight Insulin resistance Age > 40 years African American ethnicity HIV coinfection < 80% adherence (RBV > PEG-IFN)
20 Hepatitis C treatment SVR rates by fibrosis stage: CHARIOT study (genotype 1) Peg IFN alfa 2a 180 g/wk +RBV Peg IFN alfa 2a 360 g/wk + RBV 100 Virological response (%) % 71% 58% 62% 50% 51% 29% 33% 17/25 20/28 60/104 66/107 57/113 62/121 15/51 15/46 1/16 2/14 69/129 65/117 F0 F1 F2 F3 F4 N/A Metavir Stage of Fibrosis 6% 14% 53% 56% Cheng et al. EASL 2009
21 Hepatitis C treatment Relapse rates by fibrosis stage: CHARIOT study (genotype 1) Peg IFN alfa 2a 180 g/wk +RBV Peg IFN alfa 2a 360 g/wk + RBV Relapse rate (%) F0 F1 F2 F3 F4 Fibrosis score by METAVIR Cheng et al. EASL 2009
22 Hepatitis C treatment Re-treatment considerations Factors associated with non-response: - Unable to alter: genotype, HCV viral load, disease stage - Some ability to alter: obesity, alcohol intake, adherence Prior virological response best predictor of future response: - Relapsers > Non-responders (<2 log) > Null responders (<0.5 log) Some indications: - prior therapy with IFN monotherapy or IFN/RBV - PEG-IFN/RBV genotype 2/3 relapsers (if treated for 24 weeks) - heavy alcohol intake or poor adherence Staging of liver disease: - crucial to determine ongoing management strategy - stronger consideration for re-treatment if F3/4 - HCC screening if F4
23 Hepatitis C treatment REPEAT study: genotype 1 NR to PEG-IFN-2b/RBV Peg IFN alfa 2a 180 g/wk +RBV Peg IFN alfa 2a 360 g/wk + RBV SVR (%) % 7% 14% 16% 0 N=313 N= week duration N=156 N= weeks duration Jensen DM et al. AIM 2009
24 Hepatitis C treatment HCV enzymes are targets for new therapies C E1 E2 p7 NS2 NS3 NS4A NS4B NS5A NS5B NS3 Protease domain NS3 Helicase domain NS3 Bifunctional protease / helicase NS5B RNA-dependent RNA polymerase
25 Hepatitis C treatment Preclinical Phase I Phase II Phase III Protease inhibitors BILN 2061 VX-950 (Telaprevir) X (mitochondrial-cardiac toxicity) SCH (Boceprevir) BI MK-7009 TMC ITMN 191 Polymerase inhibitors HCV-796 R1626 NM-283 (Valopcitibine) X (hepatotoxicity) X (haematological toxicity) X (git toxicity) R7128 PF GS-9190
26 PROVE 1: Telaprevir Study design: Phase II, genotype 1, treatment naive PR48 (control) (n=80) Placebo + Peg-IFN + RBV Peg-IFN + RBV Follow-up T12/PR12 (n=20) TVR + Peg-IFN + RBV Follow-up T12/PR24 (n=80) TVR + Peg-IFN + RBV Peg-IFN + RBV Follow-up T12/PR48 (n=80) TVR + Peg-IFN + RBV Peg-IFN + RBV Follow-up Weeks Dosing: Peg-IFN = Peg-IFN alfa-2a 180 µg/week, RBV = RBV 1,000 or 1,200 mg/day, TVR = TVR 750 mg q8h McHutchison EASL 2008
27 PROVE 1 Early virological responses Week 4 (RVR) Week 12 (HCV RNA undetectable) 100 Subjects with undetectable HCV RNA (%) /75 PR48 34/75 10/17 12/17 T12/PR12 64/79 54/79 T12/PR24 64/79 63/79 T12/PR48 McHutchison EASL 2008
28 PROVE 1 Sustained virological response 100 SVR rate (%) * 67* /75 PR48 6/17 T12/PR12 48/79 T12/PR24 53/79 T12/PR48 McHutchison EASL 2008
29 PROVE 3: Telaprevir Study design: Phase II, PEG-IFN/RBV NRs or relapsers A (n=114) PEG/RBV B (n=113) C (n=115) D (n=111) PEG/RBV TPV PEG/RBV TPV PEG TPV Week
30 PROVE-3 Sustained virological response SVR % % 52% % 23% 0 PEG/RBV48 T24/P24 T12/PR24 T24/PR48 Manns et al EASL 2009
31 PROVE-3 Sustained virological response SVR % PEG/RBV48 T24/P24 T12/PR24 T24/PR48 NR Relapsers Manns et al EASL 2009
32 Polymerase Inhibitor (R7128): phase II Week 4 RVR (Gen 2/3, Rx experienced) RVR % % PEG/RBV 90% PEG/RBV/R7128 (1500bd) Gane et al AASLD 2008
33 Hepatitis C treatment Dosing regimens for STAT-C agents Phase Dosing Protease inhibitors Telaprevir III 750 mg q 8 hrly (1250 mg q 12 hrly phase II) Boceprevir III 800 mg tds MK 7009 II mg bd BI II mg daily TMC II mg daily Polymerase inhibitors R7128 II mg bd PF II mg bd
34 Hepatitis C update Conclusions Lifestyle factors important to potentially modify: alcohol, diet, smoking Liver disease staging crucial for treatment-decision making HCV genotype 1 response rates remain sub-optimal, particularly in context of advanced disease, high HCV viral load, HIV coinfection Many people should defer to await new therapies, particularly those with genotype 1 (esp high VL) and early liver disease Initial protease inhibitors will have significant additional toxicity, but 2 nd generation should be much more tolerable
Management of non response or relapse following HCV therapy. Greg Dore Darrell Crawford
Management of non response or relapse following HCV therapy Greg Dore Darrell Crawford Learning objectives To understand importance of characterisation of prior HCV therapy response To explore options
Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
Post AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
HCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
Hepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
New IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
PHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
New treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of
Monitoring of Treatment of viral hepatitis C
Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect
Innovazione farmacologica e farmacologia clinica
Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology
HCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
Sovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
MEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium [email protected] www.antivirals.be Pentalfa, 28
Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C
Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic
What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic Introduction Elevated liver enzymes is often not a clinical problem by itself. However it is a warning
HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
Disclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
Objectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening
Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
Update on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
Review: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
Cirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
Transmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
Clinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C)
Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C) Paul Calès Liver and Gastroenterology department, University hospital & HIFIH laboratory, Angers
Patterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Q1-2013 Conference Call - Presenting team Maris Hartmanis, CEO Charlotte
Viral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines
Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary
Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx
EVALUATION OF LIVER FIBROSIS BY FIBROSCAN
EVALUATION OF LIVER FIBROSIS BY FIBROSCAN M. Beaugrand Service d Hépatologied Hopital J. Verdier BONDY 93143 et Université Paris XIII DRESDEN 13.10.2007 ASSESSMENT OF FIBROSIS : WHY? Management of individual
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
Management of HCV/HIV co-infection in the era of DAA-based therapy
Management of HCV/HIV co-infection in the era of DAA-based therapy Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn Germany Conflict of interest I have received honoraria
PRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
Hepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver 1 1. Introduction Hepatitis C virus (HCV) infection is one of the main causes
Optimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
HEPATITIS C UPDATE: A Quarter-Century Dramatic Journey. Steve T. Chen M.D. FACP, FACG
HEPATITIS C UPDATE: A Quarter-Century Dramatic Journey Steve T. Chen M.D. FACP, FACG Hepatitis C Virus: Morphology and Characteristics Hepatitis C Virus Discovered in 1989 Nucleic Acid: 9.6 kb ssrna 40-60
Victrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD
Victrelis: hints for success Katarnya Gilbert Hepatology MSL MSD 1 Some Facts: BOC has no clinically significant activity against other HCV genotypes. Resistance with protease inhibitor monotherapy can
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred
INTRODUCTION ABSTRACT
March-April, Vol. 12 Suppl.2, 2013: s3-s35 s3 An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the
Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir
Hepatitis C Infection In Singapore
Hepatitis C Infection In Singapore Richard Guan MBBS, MRCP(UK), FAMS(Gastro), FRCP(Edin), FRCP(Lond) Gastroenterologist & Hepatologist, Mt Elizabeth Medical Centre, Singapore Summary of HCV treatment practice
HCV treatment today: pegylated interferons and ribavirin
HCV treatment today: pegylated interferons and ribavirin Other special patient populations Patients with cirrhosis Higher SVR rates are achieved in patients without cirrhosis Patients without bridging
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form
Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form For assistance, please call 1-855-552-6028 or fax completed form to 570-271-5610. Medical documentation may be requested. This
NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
Scottish Medicines Consortium
Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10
LIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
Prior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin
Coinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy